Anti-dipeptidyl-peptidase-like protein-6 (DPPX) autoimmune encephalitis associated with severe multifocal dystonia
- PMID: 40241920
- PMCID: PMC12002181
- DOI: 10.1016/j.prdoa.2025.100320
Anti-dipeptidyl-peptidase-like protein-6 (DPPX) autoimmune encephalitis associated with severe multifocal dystonia
Abstract
Anti-DPPX encephalitis is a rare form of autoimmune encephalitis characterized antibodies against a subunit of Kv4.2 potassium channels. Characteristic clinical features include cognitive dysfunction, parasomnias, psychosis, and seizures. Motor symptoms typically include myoclonus, tremor, and midline ataxia. DPPX encephalitis presenting as new-onset focal dystonia has not been previously described.
Keywords: Autoimmune encephalitis; DPPX; Dystonia; Immunotherapy; Toxin therapy.
© 2025 The Authors.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels.Ann Neurol. 2013 Jan;73(1):120-8. doi: 10.1002/ana.23756. Epub 2012 Dec 7. Ann Neurol. 2013. PMID: 23225603 Free PMC article.
-
DPPX antibody-associated encephalitis: Main syndrome and antibody effects.Neurology. 2017 Apr 4;88(14):1340-1348. doi: 10.1212/WNL.0000000000003796. Epub 2017 Mar 3. Neurology. 2017. PMID: 28258082 Free PMC article.
-
Anti-dipeptidyl-peptidase-like protein 6 encephalitis with pure cerebellar ataxia: a case report.BMC Neurol. 2022 Jul 1;22(1):242. doi: 10.1186/s12883-022-02769-0. BMC Neurol. 2022. PMID: 35778696 Free PMC article.
-
Autoimmune Encephalitis with Antibodies: Anti-NMDAR, Anti-AMPAR, Anti-GQ1b, Anti-DPPX, Anti-CASPR2, Anti-LGI1, Anti-RI, Anti-Yo, Anti-Hu, Anti-CV2 and Anti-GABAAR, in the Course of Psychoses, Neoplastic Diseases, and Paraneoplastic Syndromes.Diagnostics (Basel). 2023 Aug 3;13(15):2589. doi: 10.3390/diagnostics13152589. Diagnostics (Basel). 2023. PMID: 37568953 Free PMC article. Review.
-
Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.J Neural Transm (Vienna). 2014 Aug;121(8):1029-75. doi: 10.1007/s00702-014-1193-3. Epub 2014 Aug 1. J Neural Transm (Vienna). 2014. PMID: 25081016 Review.
References
Publication types
LinkOut - more resources
Full Text Sources